Amendment: SEC Form SCHEDULE 13D/A filed by Edgewise Therapeutics Inc.
$EWTX
Biotechnology: Pharmaceutical Preparations
Health Care
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 6)
|
Edgewise Therapeutics, Inc. (Name of Issuer) |
Common Stock, par value $0.0001 per share (Title of Class of Securities) |
28036F105 (CUSIP Number) |
Barbara Fiorini
Novo Holdings A/S, Tuborg Havnevej 19
Hellerup, G7, DK-2900
45 3527 6592
Novo Holdings A/S, Tuborg Havnevej 19
Hellerup, G7, DK-2900
45 3527 6592
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
04/23/2026
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP Number(s): | 28036F105 |
| 1 |
Name of reporting person
Novo Holdings A/S | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DENMARK
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
5,350,000.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
4.9 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
CO |
SCHEDULE 13D
|
| Item 1. | Security and Issuer | |
| (a) | Title of Class of Securities:
Common Stock, par value $0.0001 per share | |
| (b) | Name of Issuer:
Edgewise Therapeutics, Inc. | |
| (c) | Address of Issuer's Principal Executive Offices:
1715 38th St., Boulder,
COLORADO
, 80301. | |
Item 1 Comment:
This Amendment No. 6 (this "Amendment No. 6" or this "Schedule 13D/A") amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "SEC") on March 31, 2021, and amended on September 16, 2022, September 30, 2022, June 28, 2023, January 25, 2024 and September 23, 2024 (as amended, the "Statement") by the Reporting Person. This Amendment No. 6 is being filed to report the dilution of the Reporting Person's beneficial ownership in the Issuer's common stock and not as a result of any acquisition or disposition of securities by the Reporting Person. Unless otherwise defined herein, capitalized terms used in this Amendment No. 6 shall have the meanings ascribed to them in the Statement. Unless amended or supplemented below, the information in the Statement remains unchanged. | ||
| Item 5. | Interest in Securities of the Issuer | |
| (a) | Novo Holdings A/S beneficially owns 5,350,000 shares of common stock representing approximately 4.98% of the Issuer's outstanding shares of common stock, based upon 107,532,173 shares of common stock outstanding as of April 9, 2026, as reported in the Issuer's definitive proxy statement, filed with the SEC on April 23, 2026. Due to field limitations of the EDGAR filing system, the percentage listed in Row 13 of the Reporting Person's cover page has been rounded down to 4.9%. | |
| (b) | Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on the updated Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares. | |
| (c) | Novo Holdings A/S has not effected any transactions in the Issuer's common stock within the past 60 days and neither the Foundation nor any person listed on the updated Schedule I has effected any transactions in the Issuer's common stock within the past 60 days. | |
| (d) | Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares. | |
| (e) | The Reporting Person ceased to be the beneficial owner of more than five percent of the Common Stock on April 23, 2026. | |
| Item 7. | Material to be Filed as Exhibits. | |
Exhibit 99.1 Schedule I | ||
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|